13.50
0.67 (5.22%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Quanterix Corporation | Bearish | Bearish |
Stockmoo Score
|
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory, Homebrew – Custom Assay Development, and Uman NF-Light. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (Scotiabank, 107.41%) | Buy |
| Median | 24.00 (77.78%) | |
| Low | 15.00 (TD Cowen, 11.11%) | Hold |
| Average | 22.33 (65.41%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 11.61 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 12 Aug 2024 | 28.00 (107.41%) | Buy | 11.27 |
| TD Cowen | 09 Aug 2024 | 15.00 (11.11%) | Hold | 10.92 |
| Goldman Sachs | 09 Jul 2024 | 24.00 (77.78%) | Buy | 12.65 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| TOLOUE MASOUD | - | 13.03 | -368 | -4,795 |
| Aggregate Net Quantity | -368 | |||
| Aggregate Net Value ($) | -4,795 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.03 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TOLOUE MASOUD | Officer | 31 Aug 2024 | Disposed (-) | 368 | 13.03 | 4,795 |
| Date | Type | Details |
|---|---|---|
| 29 Aug 2024 | Announcement | Quanterix to Participate at the Morgan Stanley 22nd Annual Global Healthcare Conference |
| 19 Aug 2024 | Announcement | Jeffrey Elliott Appointed to Quanterix’s Board of Directors |
| 08 Aug 2024 | Announcement | Quanterix Releases Financial Results for the Second Quarter of 2024 |
| 06 Aug 2024 | Announcement | Quanterix Presenting at Canaccord Genuity 44th Annual Growth Conference |
| 31 Jul 2024 | Announcement | Quanterix To Report Second Quarter 2024 Financial Results |
| 29 Jul 2024 | Announcement | Quanterix Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer’s Disease Detection that is More Effective than Standalone Plasma p-Tau 217 |
| 17 Jun 2024 | Announcement | Quanterix to Participate at the Scotiabank Healthcare 1x1 Day |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |